Patient characteristics for hospitalized MM patients and overall data set
| . | MM hospitalized recovered, n = 299 . | MM hospitalized died, n = 203 . | All MM patients, n = 617 . |
|---|---|---|---|
| Age, y | |||
| Median [min-max] | 70 [35-92] | 72 [47-92] | 69 [34-92] |
| Sex, n (%) | |||
| Female | 126 (42.14) | 76 (37.43) | 270 (41.53) |
| Year of diagnosis, n (%) | |||
| 2020 and 2019 | 114 (38.64) | 67 (33) | 226 (35.59) |
| 2018 and 2017 and 2016 | 86 (29.15) | 69 (34) | 200 (31.50) |
| 2015 or before | 95 (32.20) | 67 (33) | 209 (32.91) |
| MGUS/MM type, n (%) | |||
| IgG | 127 (57.72) | 59 (47.96) | 255 (55.19) |
| IgA | 50 (22.72) | 30 (24.39) | 100 (21.64) |
| Light chain | 38 (17.27) | 34 (27.64) | 93 (20.12) |
| ISS stage | |||
| ISS1/2 | 164 (69.49) | 88 (61.53) | 331 (68.39) |
| ISS3 | 72 (30.50) | 55 (38.46) | 153 (31.61) |
| High-risk disease by FISH [del 17p, t(4;14), amp 1q, or t(14;16)], n (%) | |||
| Yes | 57 (23.36) | 47 (30.51) | 136 (32.07) |
| Renal disease, n (%) | |||
| Yes | 43 (21.71) | 41 (35.65) | 113 (26.52) |
| Line of treatments, n (%) | |||
| 1 or less | 156 (54.74) | 101 (51.27) | 331 (54) |
| 2 | 63 (22.10) | 48 (24.36) | 138 (22.51) |
| 3 or more | 66 (23.16) | 48 (24.36) | 144 (23.49) |
| Patient receiving active treatment, n (%) | |||
| Yes | 225 (87.20) | 131 (86.75) | 456 (83.57) |
| Prior transplant, n (%) | |||
| Yes | 118 (40.54) | 60 (32.78) | 241 (39.12) |
| Disease status, n (%) | |||
| Newly diagnosed | 134 (50.95) | 86 (44.55) | 282 (48.53) |
| MM status at COVID-19, n (%) | |||
| Active or PD | 37 (14.57) | 34 (22.97) | 87 (16.66) |
| Partial response | 143 (56.30) | 82 (55.40) | 290 (55.55) |
| Complete response | 74 (29.13) | 32 (21.62) | 145 (27.77) |
| . | MM hospitalized recovered, n = 299 . | MM hospitalized died, n = 203 . | All MM patients, n = 617 . |
|---|---|---|---|
| Age, y | |||
| Median [min-max] | 70 [35-92] | 72 [47-92] | 69 [34-92] |
| Sex, n (%) | |||
| Female | 126 (42.14) | 76 (37.43) | 270 (41.53) |
| Year of diagnosis, n (%) | |||
| 2020 and 2019 | 114 (38.64) | 67 (33) | 226 (35.59) |
| 2018 and 2017 and 2016 | 86 (29.15) | 69 (34) | 200 (31.50) |
| 2015 or before | 95 (32.20) | 67 (33) | 209 (32.91) |
| MGUS/MM type, n (%) | |||
| IgG | 127 (57.72) | 59 (47.96) | 255 (55.19) |
| IgA | 50 (22.72) | 30 (24.39) | 100 (21.64) |
| Light chain | 38 (17.27) | 34 (27.64) | 93 (20.12) |
| ISS stage | |||
| ISS1/2 | 164 (69.49) | 88 (61.53) | 331 (68.39) |
| ISS3 | 72 (30.50) | 55 (38.46) | 153 (31.61) |
| High-risk disease by FISH [del 17p, t(4;14), amp 1q, or t(14;16)], n (%) | |||
| Yes | 57 (23.36) | 47 (30.51) | 136 (32.07) |
| Renal disease, n (%) | |||
| Yes | 43 (21.71) | 41 (35.65) | 113 (26.52) |
| Line of treatments, n (%) | |||
| 1 or less | 156 (54.74) | 101 (51.27) | 331 (54) |
| 2 | 63 (22.10) | 48 (24.36) | 138 (22.51) |
| 3 or more | 66 (23.16) | 48 (24.36) | 144 (23.49) |
| Patient receiving active treatment, n (%) | |||
| Yes | 225 (87.20) | 131 (86.75) | 456 (83.57) |
| Prior transplant, n (%) | |||
| Yes | 118 (40.54) | 60 (32.78) | 241 (39.12) |
| Disease status, n (%) | |||
| Newly diagnosed | 134 (50.95) | 86 (44.55) | 282 (48.53) |
| MM status at COVID-19, n (%) | |||
| Active or PD | 37 (14.57) | 34 (22.97) | 87 (16.66) |
| Partial response | 143 (56.30) | 82 (55.40) | 290 (55.55) |
| Complete response | 74 (29.13) | 32 (21.62) | 145 (27.77) |
All MM patients includes hospitalized patients and outpatients regardless of their COVID-19–associated outcome.
FISH, fluorescence in situ hybridization; ISS, International Staging System; max, maximum; min, minimum. See Table 1 for expansion of other abbreviations.